Discrepancy on the weight of BRCA1/2 in predicting hypermutant MSS cases might be related to advanced disease stages dominating the report of Lee et al. [15], while our study focused on early T stage CRC. The gene discussed is BRCA1; the disease is colorectal carcinoma.